NCT02812342

Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.

Detailed description

This will be an open label clinical trial. We plan to treat 10 adults with AA (with at least 2 patches of alopecia involving the scalp), AT or AU with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth. Laboratory evaluation will be performed before and during treatment in order to monitor for adverse effects of the medication.

Conditions

• Alopecia Areata
• Alopecia Totalis
• Alopecia Universalis

Interventions

Type	Name	Description
DRUG	Tofacitinib ointment	Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.

Timeline

• Start date: 2016-09-01
• Primary completion: 2018-07-01
• Completion: 2018-12-01
• First posted: 2016-06-24
• Last updated: 2019-01-30
• Results posted: 2018-10-10

Locations

1 site across 1 country: United States